Drug Profile
Research programme: HuMax-CD32b antibodies - Genmab
Alternative Names: HuMax-CD32b antibodyLatest Information Update: 15 Nov 2013
Price :
$50
*
At a glance
- Originator Genmab
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Fc gamma receptor IIB antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 15 Nov 2013 Discontinued - Preclinical for Haematological malignancies in Denmark (Parenteral)
- 18 Mar 2011 No development reported - Preclinical for Haematological malignancies in Denmark (Parenteral)
- 08 Jan 2008 Preclinical trials in Haematological malignancies in Denmark (Parenteral)